Wall Street Transcript Interview with Bob McNamara, the Executive Vice President and CFO of LDR Holding Corporation (LDRH)

Wall Street Transcript

67 WALL STREET, New York - August 1, 2014 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Affordable Care Act - Aging U.S. Population - Medical Technology Innovation - Medical Equipment Growth Opportunities - Efficient Patient Treatment - Bifurcation in Medical Devices

Companies include: LDR Holding Corporation (LDRH) and many more.

In the following excerpt from the Medical Devices Report, the Executive Vice President and CFO of LDR Holding Corporation (LDRH) discusses company strategy and the outlook for this vital industry:

TWST: Could you provide an overview of the company and talk about your core competencies?

Mr. McNamara: Yes. LDR is a global company focused solely on the development of innovative technology for spinal procedures, particularly in the fastest-growing segments of the spine. We were founded in France, and our worldwide headquarters are in Austin, Texas. We have two exclusive technology platforms that represent 83% of our total revenue. The first is VerteBRIDGE plating technology, which focuses on fusion. The second is our Mobi technology, which focuses on nonfusion.

Our revenue in 2013 was $112 million, representing a growth of 23%. Within that growth, the U.S. grew 27% and makes up 74% of our total revenue. Outside the U.S. for 2013, we grew 12%, and this represents 26% of our total revenues. Founded in the year 2000, we currently have about 320 employees worldwide. We attribute our growth to our innovation and our exclusive technology.

TWST: You said that 83% of total revenue comes from that exclusive technology. Where does the remaining revenue come from?

Mr. McNamara: The remaining revenue is generated from traditional products that I would classify as commodity products; it might be pedicle screws, various implants, plates, a product called SpineTune and a product called Easyspine. These are products that I would describe as commodity products in the area of traditional fusion products.

TWST: The VerteBRIDGE and the Mobi, and correct me if am wrong, is a difference between fusion and nonfusion spinal technology. Talk about the difference between them, and do they represent sort of old school and new school in spinal surgery?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)